IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma

Malignant Melanoma Stage IV Clinical Trial

Official title: IL15-DC Vaccine in Patients With High Risk Melanoma - Exploratory Phase I/II Trial

Status Completed

Clinical Trial Summary

The purpose of the study is to gather data on feasibility as well as immune and clinical efficacy of of a dendritic cell vaccine using IL15 in patients with resected stage III or stage IV melanoma

Clinical Trial Description

IL15 is a T cell growth factor that pre-clinical data overwhelmingly suggests could have a very important role in cancer immunotherapy. A desirable property for a dendritic cell vaccine directed against cancer is the ability to efficiently prime naïve, tumor associated antigen specific T cells into potent CTLs. Results of studies in healthy volunteers have shown that IL15 DCs are particularly efficient at priming functional melanoma specific CD8+ T cells. The use of IL15 in the manufacture of the DC vaccine could result in an improved immunotherapy product. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Malignant Melanoma Stage III
• Malignant Melanoma Stage IV
• Melanoma

• NCT number: NCT01189383
• Study type: Interventional
• Source: Baylor Research Institute
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: January 2011
• Completion date: December 2016